STUB1 is an intracellular checkpoint for interferon gamma sensing

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Immune checkpoint blockade (ICB) therapy shows variable efficacy in cancer patients.
• Tumor-intrinsic resistance mechanisms limit the effectiveness of ICB.
• STUB1, an E3 ligase, was previously suggested to influence ICB response.

Purpose of the Study:

• To investigate the molecular mechanisms by which STUB1 affects ICB resistance.
• To elucidate the role of STUB1 in regulating the interferon gamma (IFNγ) pathway.
• To explore the therapeutic potential of targeting STUB1 to overcome ICB resistance.

Main Methods:

• Genetic deletion of STUB1 in cancer cells.
• Analysis of IFNγ signaling pathway components (e.g., IFNGR1, phospho-STAT1).
• Utilized techniques including Western blotting, flow cytometry, qPCR, immunopeptidomics, proteomics, and gene expression profiling.
• In vivo studies using mouse syngeneic tumor models with and without anti-PD-1 therapy.

Main Results:

• STUB1 deletion led to increased IFNGR1 surface abundance and enhanced IFNγ signaling.
• STUB1-deficient human cancer cells exhibited increased sensitivity to cytokine-induced growth inhibition.
• In vitro findings were recapitulated by blocking STUB1 protein function.
• In vivo inactivation of STUB1 did not improve anti-tumor efficacy in mouse models, even with anti-PD-1 therapy.

Conclusions:

• STUB1 acts as a negative regulator of the IFNγ response.
• Targeting STUB1 may enhance anti-tumor immunity by boosting IFNγ signaling.
• Further research is needed to assess the therapeutic benefit of STUB1 inactivation in both tumor and immune cells for ICB resistance.